Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMC-1 (famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. It is being investegated for the treatment of fib...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 09, 2023
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMC-1 (famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. It is being investegated for the treatment of fib...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 24, 2023
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMC-1 (Famciclovir) is a fixed dose combination of famciclovir and celecoxib designed to synergistically suppress herpes virus replication, with the end goal of reducing virally promoted disease symptoms. IMC-1 has been granted fast track designation by ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Thinkequity
Deal Size : Undisclosed
Deal Type : Public Offering
Virios Therapeutics, Inc. Announces Closing of Public Offering
Details : The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 (famciclovir) and for working capital and general corporate purposes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 22, 2022
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Thinkequity
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia
Details : IMC-1 (famciclovir) was well-tolerated overall, with only 4.6% of patients dropping out due to adverse events, as compared with 8.1% of placebo treated patients. No adverse event category in the IMC-1 group exceeded a 4% rate with the exception of COVID-...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 19, 2022
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Thinkequity
Deal Size : $10.0 million
Deal Type : Public Offering
Virios Therapeutics, Inc. Announces Pricing of Public Offering
Details : The Company intends to use the net proceeds from the offering primarily to further advance the clinical development of IMC-1 (famciclovir) and for working capital and general corporate purposes.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 19, 2022
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Thinkequity
Deal Size : $10.0 million
Deal Type : Public Offering
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : University Of Alabama
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Analysis of gastric mucosa biopsies revealed a significant positive association between actively replicating gastric HSV-1 and multiple functional gastrointestinal disorders, with and without concomitant FM.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 01, 2022
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : University Of Alabama
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. This dual mechanism antiviral therapy is designed to synergistically suppress herpes virus activation and replication.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 28, 2022
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Virios Therapeutics to Present at the 34th Annual Roth Conference on Monday, March 14, 2022
Details : IMC-1, a fixed-dose combination of famciclovir and celecoxib, designed to synergistically suppress herpes virus replication, with end goal of reducing virally promoted disease symptom is currently being tested in FORTRESS trial designed to set stage for ...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 08, 2022
Lead Product(s) : Famciclovir,Celecoxib
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Famciclovir
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IMC-1 is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. This dual mechanism antiviral therapy is designed to synergistically suppress HSV-1 activation and replication.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 01, 2021
Lead Product(s) : Famciclovir
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable